Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates - Gilde Healthcare

Ablynx Collaborates with Merck to Develop Therapeutic Nanobody Candidates

October 2, 2012

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX] today announced a collaboration with Merck & Co., Inc., through a subsidiary, to develop and commercialise Nanobody® candidates directed towards a voltage gated ion channel with the option to develop and commercialise a Nanobody to a second target. Merck is known as MSD outside the United States and Canada.

Under the terms of the agreement, Merck gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights to a second target. Upon signing, Merck will pay Ablynx a €6.5 million upfront payment and a €2 million fee for research funding. In addition, Ablynx will be eligible to receive up to €448 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates as well as tiered royalties on any products derived from the collaboration. Ablynx will be responsible for the discovery of Nanobody candidates and Merck will be responsible for the research, development, manufacturing and commercialisation of any Nanobody product resulting from the collaboration.

Dr Edwin Moses, Chairman and CEO of Ablynx said:

“We are delighted to initiate this collaboration with Merck in the area of ion channels where to date monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators. This agreement reflects the potential power of the Nanobody platform and the considerable success we have had to date with seven Nanobody programmes at the clinical development stage.”

“We are excited to be working with Ablynx to evaluate the potential of the Nanobody technology directed towards this challenging ion channel target,”

said Richard Hargreaves, Ph.D., Vice President and Head of Neuroscience Discovery Research at Merck.

About Ablynx’ expertise in ion channels

Ablynx has already demonstrated modulation of ion channel activity in electrophysiology assays and has identified functional Nanobodies against both voltage-gated and ligand-gated ion channels. Nanobodies can be generated to have either an agonistic (enhancing) or antagonistic (blocking) effect.

About ion channels

The physiological importance of ion channels is underlined by their involvement in a wide range of conditions including neurological disorders, hypertension, diabetes, cancer and arrhythmia. Ion channels represent highly valuable therapeutic targets which are currently modulated by a range of small molecule drugs. In 2011, sales of the top 20 best-selling ion channel drugs amounted nearly $14 billion.[1] Today, there are no approved antibody-based drugs that target ion channels.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline http://www.ablynx.com/en/research-development/pipeline/ and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023